G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 20.85 SEK -4.14% Market Closed
Market Cap: 1.4B SEK

Net Margin
Genovis AB

18.2%
Current
25%
Average
1.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.2%
=
Net Income
21.2m
/
Revenue
116.6m

Net Margin Across Competitors

No Stocks Found

Genovis AB
Glance View

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
22.46 SEK
Undervaluation 7%
Intrinsic Value
Price
G
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.2%
=
Net Income
21.2m
/
Revenue
116.6m
What is the Net Margin of Genovis AB?

Based on Genovis AB's most recent financial statements, the company has Net Margin of 18.2%.

Back to Top